<DOC>
	<DOC>NCT02957617</DOC>
	<brief_summary>The primary objective of the study is to evaluate the long-term safety and tolerability of BIIB074 in participants with neuropathic Pain From Lumbosacral Radiculopathy (PLSR). A secondary objective is to investigate the maintenance of effect during long-term treatment with BIIB074 in participants with neuropathic PLSR. For all efficacy assessments, baseline will be prior to randomization into Study 1014802-203. Another secondary objective is to evaluate the impact of treatment with BIIB074 on quality of life (QoL).</brief_summary>
	<brief_title>Extension Study to Evaluate the Long-Term Safety, Tolerability, and Maintenance of Effect of BIIB074</brief_title>
	<detailed_description>Convergence Pharmaceuticals, Ltd., registered in England, has been acquired and is now an affiliate and subsidiary of Biogen, Inc. This is an extension study to 1014802-203.</detailed_description>
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Radiculopathy</mesh_term>
	<criteria>Key Has completed Study 1014802203 for its complete duration. Key Has met an exclusion criterion for the preceding doubleblind Phase 2b study (Study 1014802203). Had a protocol deviation regarding inclusion or exclusion criteria for the doubleblind Phase 2b study (Study 1014802203). Had a treatmentrelated AE or SAE that would pose an increased risk for continued treatment with BIIB074, or discontinued study treatment in the doubleblind Phase 2b study (Study 1014802203) due to an AE or SAE. Did not return for all study visits after discontinuing treatment in the doubleblind phase of the Phase 2b study. NOTE: Other protocol defined Inclusion/Exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Neuropathic Pain From Lumbosacral Radiculopathy, PLSR</keyword>
</DOC>